Calendar

Lennar had a valid after-close date and some operational positives, including sequentially improved gross margin, lower cycle time, and a solid balance sheet, but consensus still expected EPS of $1.31 and revenue of $8.396 billion against a weak housing backdrop; the recent rebound was not enough to offset the absence of positive estimate revisions and the lack of clean accumulation.

Rejected because FedEx company IR shows fiscal fourth-quarter results were reported on June 23, 2026 and the next earnings call was scheduled for October 28, so the supplied September 16 event is not a valid pre-earnings event.

Rejected because AAR reported fiscal fourth-quarter 2026 results on July 21, 2026 and its investor-events page showed no upcoming earnings event corresponding to September 21.

AutoZone had a strong prior quarter, positive same-store sales, and a small three-month revenue-estimate improvement, but the current whisper was below consensus, EPS revisions were flat to slightly negative, the stock was down over five and twenty sessions, and the highest recent volume did not clear the 1.5x threshold on a clean accumulation day.

Thor Industries had a confirmed before-open date and some diversification support from European and supplier businesses, but EPS and revenue estimates were revised lower, management cut full-year EPS guidance, prior-quarter sales and gross margin declined, and the stock was weak into the print without verified accumulation.

KB Home had a confirmed date and a possible built-to-order operating improvement, but both EPS and revenue estimates were revised lower, prior-quarter deliveries, revenue, income, backlog, and average selling price were weak, and the stock remained sharply below late-August levels; the isolated high-volume rebound was not enough to establish an upside-surprise setup.

Rejected because Ferguson reported fiscal second-quarter 2026 results on August 10, 2026 and company materials indicated the next results were expected November 9, not September 22.

Recent-news and social coverage are sparse. The checked August 20 SEC filing was a strategic-cooperation disclosure rather than an earnings release, so earnings surprise, guidance, analyst revision and post-print reaction evidence remain unavailable. Sentiment is best treated as neutral and monitoring-oriented despite the event headline.

The T+3 follow-up remains a cautious monitoring view. The August 11 10-Q is the latest confirmed company financial source; no dated August 17 earnings release, transcript, analyst revision, or target-change data was identified in the checked company-source results. News tone is mixed-to-negative because financing and sector-pressure headlines offset mission and contract progress. Social, options, short-interest, and employee-sentiment data were not supplied, and no earnings-specific price-reaction attribution was confirmed. [#SEC-10Q-2026-08-11]

The post-earnings evidence is mixed but eventful: the company disclosed treasury growth, FDA alignment, and a major mining-asset transaction, offset by the clinical endpoint miss and potential dilution. The August 19 anchor price of $1.07 does not establish a trustworthy market-reaction attribution, and analyst revisions remain unavailable. Low coverage and loose peers warrant monitoring-style conviction rather than a strong directional thesis.

This is a cautious post-earnings monitoring view because the packet's August 17 trigger conflicts with the company's confirmed August 27 earnings schedule. Recent news coverage is sparse and largely not company-specific; social, options, short-interest, and employee-sentiment data are unavailable. The positive deterministic prior is supported by prior operating momentum, but forward confirmation is still pending.

The post-earnings signal is mixed but modestly constructive: the company reported a small revenue beat and stronger gaming mix, while profit and paying users declined. YALA closed at US$5.34 on August 17 and the RankAlpha anchor was US$5.51 on August 19, but no trusted source attributes the move directly to earnings. Social data, analyst revisions, and target-change evidence are unavailable, so this remains a low-conviction monitoring view.

News tone remains positive because of the announced merger and ongoing surgical growth, but the Q2 report was mixed: adjusted EPS beat while revenue missed consensus and GAAP operating profitability weakened. The current price is close to headline merger value, so the setup is primarily event-driven with limited incremental upside. Post-print analyst revisions and market-reaction attribution are unavailable; social, options, short-interest, and employee-review data are also unavailable, reducing confidence.

Coya Therapeutics Reports Second Quarter 2026 Financial Results and Provides a Corporate Update